JAK2 and thrombocytosis disease: In addition, jak-stat signaling in zebrafish can also be inhibited by JAK2 inhibitors used in clinical trials illustrating that the conserved signaling machinery in human and zebrafish.42, 43, 44 Our data showed that ruxolitinib treatment results in a dose-dependent inhibitory effect on both normal thrombopoiesis and thrombocytosis caused by mutant CALR in zebrafish.